Testing a Vaccine for Treating or Preventing Triple-Negative Breast Cancer identifier:
NCT04674306 (

Treatment study for people with stage 2 or 3 triple-negative breast cancer at high risk for recurrence.

Study Contact Information:

Contact: George T Budd, MD      
[email protected]

About the Study

Researchers are studying the affects of this breast cancer vaccine on the immune system in the following groups:

This listing is for people who have been diagnosed with triple-negative breast cancer. If you have never been diagnosed with cancer and are interested in joining the prevention portion of the study, see our study listing here

What the Study Involves 

All participants will receive the vaccinations every 2 weeks for a total of 3 doses. 

Study Location

Cleveland, Ohio 
Cleveland Clinic Case Comprehensive Cancer Center
Contact: George T Budd, MD      
[email protected]

This Study is Open To:

People 18 years or older with the following may be eligible to participate in one of the treatment groups:

Both Groups:

Triple Negative Group:

Keytruda Group

For the full listing visit the website

This Study is Not Open To:

People with the following may not be eligible to participate:

For the full listing visit the website


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.